**Trader consensus heavily favors no new COVID variant of concern before 2027 at 85% implied probability**, driven by the absence of any WHO or ECDC-designated VOC since early Omicron sublineages. Ongoing genomic surveillance tracks divergent strains such as BA.3.2 (Cicada), XFG (Stratus), and NB.1.8.1 (Nimbus), yet these remain classified only as variants under monitoring with low assessed public health risk and no evidence of substantially increased severity or immune escape warranting escalation. Recent 2025–2026 data show these Omicron descendants circulating at stable or declining prevalence without triggering new waves or policy shifts, while updated vaccines target related lineages. This pattern of contained evolution, backed by consistent low-risk evaluations through mid-2026, underpins the strong market lean against a qualifying new VOC emerging in the remaining timeframe.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoSí
$241,359 Vol.
$241,359 Vol.
Sí
$241,359 Vol.
$241,359 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Mercado abierto: Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...**Trader consensus heavily favors no new COVID variant of concern before 2027 at 85% implied probability**, driven by the absence of any WHO or ECDC-designated VOC since early Omicron sublineages. Ongoing genomic surveillance tracks divergent strains such as BA.3.2 (Cicada), XFG (Stratus), and NB.1.8.1 (Nimbus), yet these remain classified only as variants under monitoring with low assessed public health risk and no evidence of substantially increased severity or immune escape warranting escalation. Recent 2025–2026 data show these Omicron descendants circulating at stable or declining prevalence without triggering new waves or policy shifts, while updated vaccines target related lineages. This pattern of contained evolution, backed by consistent low-risk evaluations through mid-2026, underpins the strong market lean against a qualifying new VOC emerging in the remaining timeframe.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes